EDITORIAL URRENT PINION Reinhard Dummer Ten years ago, surgery was the only reliable treat- immunotherapies, or we can use other immune ment option in most skin cancers. Medical therapy modulators such as anti-tumor necrosis factor including chemotherapy was standard of care with- strategies earlier. out any benefit concerning overall survival. Moreover, we can search for additional combi- Many patients with advanced melanoma nation agents that are specifically selected for the individual patient, such as concept precision immu- received monochemotherapy with dacarbazine for metastatic disease. Others were treated with high- notherapy. With this, there is a good chance that dose interleukin 2. This treatment causes substantial the overall outcome of immunotherapy will be side-effects and many medical complications. improved. A new molecule in development is epa- In the adjuvant situation, high-dose interferon a cadostat, an IDO1 inhibitor that has demonstrated was used. Interferon a has an impact on the out- promising progression-free survival, as well as come, however, again this therapy was quiet toxic. a good response rate and favorable safety profile Many patients suffered for months from flu-like compared with current monotherapies. symptoms and some also from depression. On the Targeted therapies achieve response rates of basis of a
Current Opinion in Oncology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud